Active Not Recruiting NA INTERVENTIONAL 1-arm NCT05155605

PATHFINDER 2: a Multi-Cancer Early Detection Study

The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population

Sponsor: GRAIL, Inc.

Conditions Cancer Early Detection of Cancer

Interventions Multi-Cancer Early Detection Test

Updated 17 times since 2022 Last updated: Dec 24, 2024 Started: Dec 8, 2021 Primary completion: Feb 28, 2026 Completion: Apr 30, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Cancer and Early Detection of Cancer and is currently ongoing. GRAIL, Inc. leads this study, which shows 17 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

17 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting NA
Feb 2025 — Sep 2025 [monthly]

Active Not Recruiting NA
Sep 2024 — Feb 2025 [monthly]

Active Not Recruiting NA
Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting NA

Status: Recruiting → Active Not Recruiting
Jul 2024 — Aug 2024 [monthly]

Recruiting NA

▶ Show 12 earlier versions

Apr 2024 — Jul 2024 [monthly]

Recruiting NA
Jan 2024 — Apr 2024 [monthly]

Recruiting NA
Oct 2023 — Jan 2024 [monthly]

Recruiting NA
Aug 2023 — Oct 2023 [monthly]

Recruiting NA
May 2023 — Aug 2023 [monthly]

Recruiting NA
Apr 2023 — May 2023 [monthly]

Recruiting NA
Mar 2023 — Apr 2023 [monthly]

Recruiting NA
Sep 2022 — Mar 2023 [monthly]

Recruiting NA
Jun 2022 — Sep 2022 [monthly]

Recruiting NA
May 2022 — Jun 2022 [monthly]

Recruiting NA
Feb 2022 — May 2022 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Jan 2022 — Feb 2022 [monthly]

Not Yet Recruiting NA

First recorded

Dec 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GRAIL, Inc.

Data source: GRAIL, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amarillo, United States , Annapolis, United States , Asheville, United States , Atlanta, United States , Auburn, United States , Austin, United States , Baton Rouge, United States , Bend, United States , Chicago, United States , Cleveland, United States and 39 more locations